Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. Issue 6 (November 2013)

• Record Type: Journal Article
• Authors: Strunets, Anton; Mirza, Mahek; Sra, Jasbir; Jahangir, Arshad
• Is Part Of: Expert review of clinical pharmacology. Volume 6:Issue 6(2013)
• Page Start: 677
• Page End: 689
• Publication Date: 2013-11
• Subjects: atrial fibrillation -- apixaban -- bleeding -- dabigatran -- drug–drug interaction -- elderly novel anticoagulants -- rivaroxaban -- stroke -- warfarin; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2013.842125
• Languages: English
• ISSNs: 1751-2433

Abstract

Vitamin K antagonists (VKAs) are the most widely used anticoagulants for stroke prevention in patients with atrial fibrillation (AF). Recently, the US FDA approved three novel anticoagulants that work through inhibition of coagulation cascade independent of Vitamin K-dependent enzymatic reactions and, therefore, should have less food–drug interactions. Since AF is a disease of the aging heart, it is important to assess safety and efficacy of these new anticoagulants in elderly patients. We reviewed age-related changes in pharmacokinetics and pharmacodynamics observed with senescence and the effects of these changes on novel anticoagulants, known and anticipated drug and food interactions, and challenges related to bleeding complications and temporary discontinuation prior to surgery or interventional procedure. Although advantageous to VKA in age groups represented in trials, there are lack of data on VKA usage in older–elderly patients; additional research and post-marketing analysis in older–elderly patients are needed.